Biomarker Development in COPD: Moving From P Values to Products to Impact Patient Care

Chest

Volumn 151, Issue 2, 2017, Pages 455-467

  Hollander, Zsuzsanna ^a,b,c   DeMarco, Mari L ^b   Sadatsafavi, Mohsen ^b,d   McManus, Bruce M ^a,b,c   Ng, Raymond T ^a,b,c   Sin, Don D ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c PROOF Centre of Excellence   (Canada)

^d VANCOUVER COASTAL HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

biomarkers; COPD; personalized medicine

Indexed keywords

25 HYDROXYVITAMIN D; AFATINIB; ALPHA 1 ANTITRYPSIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTIINFLAMMATORY AGENT; BENRALIZUMAB; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; BRONCHODILATING AGENT; CRIZOTINIB; ERLOTINIB; GEFITINIB; INTERLEUKIN 5 RECEPTOR; LEBRIKIZUMAB; MEPOLIZUMAB; MUSCARINIC RECEPTOR BLOCKING AGENT; OMALIZUMAB; TRANSCRIPTION FACTOR RUNX2; TROPONIN T; VITAMIN D;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL DECISION MAKING; CLINICAL STUDY; DIAGNOSTIC EQUIPMENT; DIAGNOSTIC TEST; DISEASE EXACERBATION; EOSINOPHIL COUNT; FLUORESCENCE IN SITU HYBRIDIZATION; FORCED EXPIRATORY VOLUME; GENE REARRANGEMENT; HEALTH ECONOMICS; HUMAN; LUNG FUNCTION; MYCOBACTERIUM TUBERCULOSIS; NON SMALL CELL LUNG CANCER; NONHUMAN; PATIENT CARE; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION SYSTEM; PROGNOSIS; REVIEW; STATISTICAL SIGNIFICANCE; COST BENEFIT ANALYSIS; DISEASE COURSE; METABOLISM; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME;

BIOMARKERS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FORCED EXPIRATORY VOLUME; HUMANS; PRECISION MEDICINE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME;

EID: 85011590030     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2016.09.012     Document Type: Review

References (81)

1. 1 Ma, J., Ward, E.M., Siegel, R.L., et al. Temporal trends in mortality in the United States, 1969-2013. JAMA 314:16 (2015), 1731–1739.
2. 2 Lozano, R., Naghavi, M., Foreman, K., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:9859 (2012), 2095–2128.
3. 3 Adeloye, D., Chua, S., Lee, C., et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health, 5(2), 2015, 020415.
4. 4 COPD Foundation. Impact of COPD on health care costs. https://www.copdfoundation.org/pdfs/Impact%20on%20Costs.pdf. Accessed June 21, 2016.
5. 5 Centers for Disease Control and Prevention. Increase expected in medical care costs for COPD. http://www.cdc.gov/features/ds-copd-costs/. Accessed June 21, 2016.
6. 6 Center for Disease Control and Prevention. Current cigarette smoking among adults –United States, 2011. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6144a2.htm?s_cid=%20mm6144a2.htm_w. Accessed June 21, 2016.
7. 7 Ford, E.S., Trends in mortality from COPD among adults in the United States. Chest 148:4 (2015), 962–970.
8. 8 Ford, E.S., Hospital discharges, readmissions, and ED visits for COPD or bronchiectasis among US adults: findings from the nationwide inpatient sample 2001-2012 and Nationwide Emergency Department Sample 2006-2011. Chest 147:4 (2015), 989–998.
9. 9 Niewoehner, D.E., Clinical practice. Outpatient management of severe COPD. N Engl J Med 362:15 (2010), 1407–1416.
10. 10 Lange, P., Celli, B., Agusti, A., et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med 373:2 (2015), 111–122.
11. 11 United States Food and Drug Administration. Guidance for industry: chronic obstructive pulmonary disease: developing drugs for treatment. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071575.pdf. Accessed June 21, 2016.
12. 12 Miller, B.E., Tal-Singer, R., Rennard, S.I., et al. Plasma fibrinogen qualification as a drug development tool in chronic obstructive pulmonary disease. Perspective of the Chronic Obstructive Pulmonary Disease Biomarker Qualification Consortium. Am J Respir Crit Care Med 193:6 (2016), 607–613.
13. 13 Sin, D.D., Hollander, Z., DeMarco, M.L., et al. Biomarker development for chronic obstructive pulmonary disease. From discovery to clinical implementation. Am J Respir Crit Care Med 192:10 (2015), 1162–1170.
14. 14 Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:3 (2001), 89–95.
15. 15 Jameson, J.L., Longo, D.L., Precision medicine–personalized, problematic, and promising. N Engl J Med 372:23 (2015), 2229–2234.
16. 16 FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. 2016, Food and Drug Administration/National Institutes of Health, Silver Spring, MD.
17. 17 Committee on the Review of Omics-based Tests for Predicting Patient Outcomes in Clinical Trials, Board on Health Care Services, Board on Health Sciences Policy, Institute of Medicine. Evolution of Translational Omics: Lessons Learned and the Path Forward. 2012, The National Academies Press, Washington, DC.
18. 18 Tashkin, D.P., Celli, B., Senn, S., et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359:15 (2008), 1543–1554.
19. 19 Vestbo, J., Anderson, J.A., Brook, R.D., et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet 387:10030 (2016), 1817–1826.
20. 20 Celli, B.R., Thomas, N.E., Anderson, J.A., et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 178:4 (2008), 332–338.
21. 21 Lapperre, T.S., Snoeck-Stroband, J.B., Gosman, M.M., et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 151:8 (2009), 517–527.
22. 22 Vestbo, J., Edwards, L.D., Scanlon, P.D., et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 365:13 (2011), 1184–1192.
23. 23 Zafari, Z., Sin, D.D., Postma, D.S., et al. Individualized prediction of lung-function decline in chronic obstructive pulmonary disease. CMAJ 188:14 (2016), 1004–1011.
24. 24 Rennard, S.I., Dale, D.C., Donohue, J.F., et al. CXCR2 Antagonist MK-7123. A phase 2 proof-of-concept trial for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 191:9 (2015), 1001–1011.
25. 25 Mannino, D.M., Davis, K.J., Lung function decline and outcomes in an elderly population. Thorax 61:6 (2006), 472–477.
26. 26 Agusti, A., Calverley, P.M., Celli, B., et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res, 11, 2010, 122.
27. 27 Hurst, J.R., Vestbo, J., Anzueto, A., et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363:12 (2010), 1128–1138.
28. 28 Roede, B.M., Bindels, P.J., Brouwer, H.J., et al. Antibiotics and steroids for exacerbations of COPD in primary care: compliance with Dutch guidelines. Br J Gen Pract 56:530 (2006), 662–665.
29. 29 Wedzicha, J.A., Decramer, M., Ficker, J.H., et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 1:5 (2013), 199–209.
30. 30 Calverley, P.M., Rabe, K.F., Goehring, U.M., et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374:9691 (2009), 685–694.
31. 31 Decramer, M., Anzueto, A., Kerwin, E., et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med 2:6 (2014), 472–486.
32. 32 Aaron, S.D., Donaldson, G.C., Whitmore, G.A., et al. Time course and pattern of COPD exacerbation onset. Thorax 67:3 (2012), 238–243.
33. 33 Pauwels, R., Calverley, P., Buist, A.S., et al. COPD exacerbations: the importance of a standard definition. Respir Med 98:2 (2004), 99–107.
34. 34 Anthonisen, N.R., Manfreda, J., Warren, C.P., et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 106:2 (1987), 196–204.
35. 35 Cazzola, M., Di Perna, F., D'Amato, M., et al. Formoterol Turbuhaler for as-needed therapy in patients with mild acute exacerbations of COPD. Respir Med 95:11 (2001), 917–921.
36. 36 Thompson, W.H., Nielson, C.P., Carvalho, P., et al. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 154:2 Pt 1 (1996), 407–412.
37. 37 Jaiswal, A., Chichra, A., Nguyen, V.Q., et al. Challenges in the management of patients with chronic obstructive pulmonary disease and heart failure with reduced ejection fraction. Curr Heart Fail Rep 13:1 (2016), 30–36.
38. 38 Wang, W.Q., Huang, H.L., Zhu, S., et al. High-sensitivity cardiac troponin T in patients with acute myocardial infarction in acute exacerbation of chronic obstructive pulmonary disease. Clin Lab 61:8 (2015), 1083–1093.
39. 39 Rizkallah, J., Man, S.F., Sin, D.D., Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis. Chest 135:3 (2009), 786–793.
40. 40 Leidy, N.K., Wilcox, T.K., Jones, P.W., et al. Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diary. Am J Respir Crit Care Med 183:3 (2011), 323–329.
41. 41 Aquinox. Aquinox Pharmaceuticals announces results from FLAGSHIP Trial with AQX-1125 in chronic obstructive pulmonary disease patients with frequent exacerbations. http://investor.aqxpharma.com/releasedetail.cfm?releaseid=921316. Accessed June 21, 2016.
42. 42 Hurst, J.R., Donaldson, G.C., Perera, W.R., et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 174:8 (2006), 867–874.
43. 43 Asiimwe, A.C., Brims, F.J., Andrews, N.P., et al. Routine laboratory tests can predict in-hospital mortality in acute exacerbations of COPD. Lung 189:3 (2011), 225–232.
44. 44 Abroug, F., Ouanes-Besbes, L., Nciri, N., et al. Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disease: diagnostic performance of cardiac biomarkers. Am J Respir Crit Care Med 174:9 (2006), 990–996.
45. 45 U.S. Food and Drug Administration. Medical devices: companion diagnostics. U.S. Department of Health and Human Services website. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm407297.htm. Accessed June 21, 2016.
46. 46 cobas. The cobas® EGFR Mutation Test v.2. http://www.cobasegfrtest.com/. Accessed June 21, 2016.
47. 47 Solomon, B.J., Mok, T., Kim, D.W., et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:23 (2014), 2167–2177.
48. 48 Cataldo, V.D., Gibbons, D.L., Perez-Soler, R., et al. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 364:10 (2011), 947–955.
49. 49 Busse, W.W., Morgan, W.J., Gergen, P.J., et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 364:11 (2011), 1005–1015.
50. 50 Ramsey, B.W., Davies, J., McElvaney, N.G., et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365:18 (2011), 1663–1672.
51. 51 Chapman, K.R., Burdon, J.G., Piitulainen, E., et al. Intravenous augmentation treatment and lung density in severe alpha1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet 386:9991 (2015), 360–368.
52. 52 Fishman, A., Martinez, F., Naunheim, K., et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 348:21 (2003), 2059–2073.
53. 53 Martineau, A.R., James, W.Y., Hooper, R.L., et al. Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease (ViDiCO): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med 3:2 (2015), 120–130.
54. 54 Lehouck, A., Mathieu, C., Carremans, C., et al. High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 156:2 (2012), 105–114.
55. 55 Pascoe, S., Locantore, N., Dransfield, M.T., et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 3:6 (2015), 435–442.
56. 56 Pavord, I.D., Lettis, S., Locantore, N., et al. Blood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPD. Thorax 71:2 (2016), 118–125.
57. 57 Brightling, C.E., Bleecker, E.R., Panettieri, R.A. Jr., et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med 2:11 (2014), 891–901.
58. 58 Pharmacy Times. COPD: evaluating the pipeline. http://www.pharmacytimes.com/publications/directions-in-pharmacy/2015/march2015/copd-evaluating-the-pipeline. Accessed June 21, 2016.
59. 59 Corren, J., Lemanske, R.F., Hanania, N.A., et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 365:12 (2011), 1088–1098.
60. 60 Aaron, S.D., Vandemheen, K.L., Maltais, F., et al. TNFalpha antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial. Thorax 68:2 (2013), 142–148.
61. 61 Woodruff, P.G., Agusti, A., Roche, N., et al. Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet 385:9979 (2015), 1789–1798.
62. 62 Ioannidis, J.P., Allison, D.B., Ball, C.A., et al. Repeatability of published microarray gene expression analyses. Nat Genet 41:2 (2009), 149–155.
63. 63 Obeidat, M., Hao, K., Bosse, Y., et al. Molecular mechanisms underlying variations in lung function: a systems genetics analysis. Lancet Respir Med 3:10 (2015), 782–795.
64. 64 Ioannidis, J.P., Why most published research findings are false. PLoS Med, 2(8), 2005, e124.
65. 65 Ioannidis, J.P., How to make more published research true. PLoS Med, 11(10), 2014, e1001747.
66. 66 Subramanian, J., Simon, R., Overfitting in prediction models - is it a problem only in high dimensions?. Contemp Clin Trials 36:2 (2013), 636–641.
67. 67 Rifai, N., Gillette, M.A., Carr, S.A., Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 24:8 (2006), 971–983.
68. 68 Annesley, T.M., Cooks, R.G., Herold, D.A., et al. Clinical mass spectrometry-achieving prominence in laboratory medicine. Clin Chem 62:1 (2016), 1–3.
69. 69 Fung, E.T., A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin Chem 56:2 (2010), 327–329.
70. 70 U.S. Food and Drug Administration. Regulatory information: Federal Food, Drug and Cosmetic Act (FD&C Act). U.S. Department of Health and Human Services website. http://www.fda.gov/regulatoryinformation/legislation/federalfooddrugandcosmeticactfdcact/. Accessed June 21, 2016.
71. 71 U.S. Government Publishing Office. 21 U. S. C. 360C - classification of devices intended for human use. https://www.gpo.gov/fdsys/granule/USCODE-2010-title21/USCODE-2010-title21-chap9-subchapV-partA-sec360c/content-detail.html. Accessed June 21, 2016.
72. 72 U.S. Food and Drug Administration. Medical devices: classify your medical device. U.S. Department of Health and Human Services website. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/ClassifyYourDevice/. Accessed June 19, 2016.
73. 73 U.S. Food and Drug Administration. CFR - code of federal regulations title 21. U.S. Department of Health and Human Services website. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=866.5270. Accessed June 21, 2016.
74. 74 U.S. Food and Drug Administration. CFR - code of federal regulations title 21. U.S. Department of Health and Human Services website. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=866.3372. Accessed June 21, 2016.
75. 75 Zhao, Z., Sacks, D., Assay Development in Pathobiology of Human Disease. A Dynamic Encyclopedia of Disease Mechanisms. 2014, Academic Press, Cambridge, MA, 3194–3206.
76. 76 Regnier, F.E., Skates, S.J., Mesri, M., et al. Protein-based multiplex assays: mock presubmissions to the US Food and Drug Administration. Clin Chem 56:2 (2010), 165–171.
77. 77 Avorn, J., The $2.6 billion pill–methodologic and policy considerations. N Engl J Med 372:20 (2015), 1877–1879.
78. 78 U.S. Food and Drug Administration. Biomarker qualification program. Department of Health and Human Services website. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/ucm284076.htm. Accessed June 21, 2016.
79. 79 Buxton, M.J., Drummond, M.F., Van Hout, B.A., et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 6:3 (1997), 217–227.
80. 80 Caro, J.J., Briggs, A.H., Siebert, U., et al. Modeling good research practices–overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–1. Value Health 15:6 (2012), 796–803.
81. 81 Karnon, J., Stahl, J., Brennan, A., et al. Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–4. Value Health 15:6 (2012), 821–827.